182 related articles for article (PubMed ID: 22198829)
1. Interstitial pneumonitis associated with the immunomodulatory drugs thalidomide and lenalidomide.
Iino M
Int J Hematol; 2012 Feb; 95(2):223-4. PubMed ID: 22198829
[No Abstract] [Full Text] [Related]
2. Drug-induced interstitial pneumonitis due to low-dose lenalidomide.
Kunimasa K; Ueda T; Arita M; Maeda T; Hotta M; Ishida T
Intern Med; 2012; 51(9):1081-5. PubMed ID: 22576392
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide-induced interstitial lung disease.
Chen Y; Kiatsimkul P; Nugent K; Raj R
Pharmacotherapy; 2010 Mar; 30(3):325. PubMed ID: 20180616
[TBL] [Abstract][Full Text] [Related]
4. Lung Toxicity after Lenalidomide Treatment in a Patient with Multiple Myeloma.
Cabrera César E; Fernández Aguirre MC; González Fernández A
Arch Bronconeumol; 2017 Jun; 53(6):355-356. PubMed ID: 27939513
[No Abstract] [Full Text] [Related]
5. Pomalidomide-Induced Pulmonary Toxicity in Multiple Myeloma.
Modi D; Mamdani H; Vettese T
Am J Med Sci; 2015 Sep; 350(3):241-2. PubMed ID: 26200951
[No Abstract] [Full Text] [Related]
6. Lenalidomide-induced acute interstitial nephritis.
Lipson EJ; Huff CA; Holanda DG; McDevitt MA; Fine DM
Oncologist; 2010; 15(9):961-4. PubMed ID: 20709889
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study.
Luo J; Gagne JJ; Landon J; Avorn J; Kesselheim AS
Eur J Cancer; 2017 Jan; 70():22-33. PubMed ID: 27866096
[TBL] [Abstract][Full Text] [Related]
8. How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide.
Kastritis E; Dimopoulos M
Leuk Lymphoma; 2007 Dec; 48(12):2295-7. PubMed ID: 18066998
[No Abstract] [Full Text] [Related]
9. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.
Niesvizky R; Martínez-Baños D; Jalbrzikowski J; Christos P; Furst J; De Sancho M; Mark T; Pearse R; Mazumdar M; Zafar F; Pekle K; Leonard J; Jayabalan D; Coleman M
Leuk Lymphoma; 2007 Dec; 48(12):2330-7. PubMed ID: 18067007
[TBL] [Abstract][Full Text] [Related]
10. Side effects and good effects from new chemotherapeutic agents. Case 2. Thalidomide-induced interstitial pneumonitis.
Onozawa M; Hashino S; Sogabe S; Haneda M; Horimoto H; Izumiyama K; Kondo T; Aldana LP; Hamada K; Asaka M
J Clin Oncol; 2005 Apr; 23(10):2425-6. PubMed ID: 15800335
[No Abstract] [Full Text] [Related]
11. Diffuse alveolar hemorrhage associated with lenalidomide.
Sakai M; Kubota T; Kuwayama Y; Ikezoe T; Yokoyama A
Int J Hematol; 2011 Jun; 93(6):830-831. PubMed ID: 21573890
[No Abstract] [Full Text] [Related]
12. Immunomodulatory analogues of thalidomide in the treatment of multiple myeloma.
Suppiah R; Srkalovic JG; Hussein MA
Clin Lymphoma Myeloma; 2006 Jan; 6(4):301-5. PubMed ID: 16507207
[TBL] [Abstract][Full Text] [Related]
13. Neutrophilic dermatosis complicating lenalidomide therapy.
Thieu KP; Rosenbach M; Xu X; Kist JM
J Am Acad Dermatol; 2009 Oct; 61(4):709-10. PubMed ID: 19577327
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma.
Jena RK; Swain TR; Kansurkar SS; Swain M
Eur J Clin Pharmacol; 2012 May; 68(5):881-4. PubMed ID: 22127618
[TBL] [Abstract][Full Text] [Related]
15. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
16. Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide.
Thornburg A; Abonour R; Smith P; Knox K; Twigg HL
Chest; 2007 May; 131(5):1572-4. PubMed ID: 17494808
[TBL] [Abstract][Full Text] [Related]
17. Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma: Case Report.
Walavalkar V; Adey DB; Laszik ZG; Jen KY
Transplant Proc; 2018 Apr; 50(3):873-876. PubMed ID: 29661456
[TBL] [Abstract][Full Text] [Related]
18. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Lacy MQ; Tefferi A
Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
[TBL] [Abstract][Full Text] [Related]
19. [Safety and effectiveness of low-dose lenalidomide therapy for multiple myeloma complicated with bortezomib-associated interstitial pneumonia].
Nagamachi Y; Yamauchi N; Muramatsu H; Okamoto T; Inomata H; Nozawa E; Koyama R; Ihara K; Nishisato T; Yamada H; Yano T; Tanaka S; Ono K; Kikuchi S; Kato J
Rinsho Ketsueki; 2013 May; 54(5):451-6. PubMed ID: 23727683
[TBL] [Abstract][Full Text] [Related]
20. Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature.
Martin MG; Vij R
Clin Lymphoma Myeloma; 2009 Aug; 9(4):320-3. PubMed ID: 19717384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
